contraception
Women's health · 2013–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| etonogestrel with ethinylestradiol Contraception for women seeking contraception. The submission proposed restricting to women with difficulty swallowing tablets, gastrointestinal disturbances… | May 2025 | Recommended with restriction | input received National Aboriginal Community Controlled Health Organisation |
| estetrol with drospirenone Combined oral contraceptive for women of reproductive age seeking a form of oral contraception to prevent pregnancy. | Mar 2025 | Recommended with restriction | 1 individuals National Aboriginal Community Controlled Health Organisation |
| drospirenone Contraception in women. Drospirenone is a newer generation progestogen-only pill (POP) indicated for women requesting contraception, particularly those with… | Nov 2024 | Recommended | 17 individuals Research Institute |
| medroxyprogesterone acetate Contraception. Medroxyprogesterone acetate 150 mg/mL pre-filled syringe is indicated for use as a reversible hormonal contraceptive method. | Nov 2023 | Recommended | none received |
| levonorgestrel Contraception for up to 5 years in women requesting contraception. | Mar 2019 | Recommended with restriction | input received |
| levonorgestrel Contraception for up to 3 years using an intrauterine levonorgestrel-releasing system. | Mar 2014 | Recommended | no section in document |
| levonorgestrel Contraception for up to 3 years using a levonorgestrel-releasing intrauterine system. | Jul 2013 | Recommended | no section in document |
Who spoke
National Aboriginal Community Controlled Health Organisation · Research Institute
What the PBS pays
$60M in government benefit over 2024–25, across 1,217,662 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| levonorgestrel | $29.5M |
| etonogestrel with ethinylestradiol | $19.6M |
| drospirenone | $4.1M |
| estetrol with drospirenone | $4.1M |
| medroxyprogesterone acetate | $2.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.